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Vigabatrin (GVG) and lamotrigine (LTG) are new antiepileptic drugs (AEDs) individually et~ective as add-on 
therapy for refractory seizures. The efficacy of GVG and LTG in combination was evaluated in a prospective audit 
of 42 patients with intractable pilepsy. There was a statistically significant median reduction of 62% (P < 0.025) 
from a median baseline monthly seizure frequency (MSF) of 29 (mean 59, 95% CI 22, 96) to a median MSF of 11 
(mean 23, 95% CI 8, 38) during a median treatment period of eight months, with a greater than 50% reduction in 
MSF in 29 patients (69%) treated with the add-on combination of GVG and LTG. The additional MSF reduction 
achieved by the combination amounted to 21% (18% when GVG was added to LTG and 24% when LTG was 
added to GVG). The median trough plasma lamotrigine concentration was 9.9 mg/I (range 3.4-19.6 mg/I). The 
average daily dose of LTG was 517 mg (range, 175-800 mg) and GVG 2400 mg (range, 1500-3500 mg). Adverse 
events requiring alteration of therapy occurred in 24 patients (57%) with a drop-out rate of 12%. The combination 
of GVG and LTG should be considered as a therapeutic option in patients with intractable pilepsy. The results of 
the present study support the need to confirm additive antiepileptic efficacy of GVG and LTG by conducting 
controlled trials of this combination therapy. 
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INTRODUCTION 
One in five patients with newly diagnosed 
epilepsy develop complex partial seizures which 
cannot be controlled by conventional AEDs and 
may be considered for temporal lobectomy t. 
Patients with the Lennox-Gastaut syndrome 
(LGS) are often so handicapped by medically 
refractory tonic and atonic seizures that the 
operation of section of the corpus callosum may 
be performed as a palliative procedure 2. GVG 
and LTG are newly developed AEDs, each of 
which has been shown to be effective in 
controlled trials of add-on therapy in patients 
with refractory partial seizures 3. LTG may be 
particularly effective against secondarily general- 
ized and tonic seizures 4"5. GVG appears to be 
most effective in controlling complex partial 
seizures 6.
From December 1990 to April 1991 LTG was 
added to GVG and the conventional AEDS of 
four patients who had a long-standing history of 
refractory complex partial and tonic seizures. 
This was done because of limited antiepileptic 
response in these patients to single add-on 
therapy with either GVG or LTG, taking into 
account the pharmacological potential of novel 
AEDS, such as LTG and GVG, to have additive 
efficacy. There was also a report from the UK of 
apparent improvement in seizure control follow- 
ing the combination of GVG and LTG 7. Impro- 
vement in seizure control was observed in these 
four patients over the ensuing six months when 
the LTG dose was stepped up to achieve a trough 
plasma level between 5 and 15mg/1 without 
intolerable side-effects. The aim of the present 
study was to determine whether GVG and LTG 
in combination would be consistently effective for 
treating a larger number of patients with intrac- 
table epilepsy over an extended period of time. 
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PATIENTS AND METHODS 
Patients 
A total population of 42 patients with intractable 
epilepsy (22 males and 20 females, median age 31; 
range, 13-40 years) was treated with the com- 
bination of GVG and LTG as add-on therapy. 
Approval was obtained from the hospital's Ethics 
of Research Committee and informed consent 
was obtained from the patients or their guardians 
and care-givers according to NH and MRC 
guidelines. The median duration of epilepsy was 
21 years (range, 4-36 years)'. 
Epi lepsies and seizures 
Localization-related epilepsy (LRE)-was diag- 
nosed in 32 patients, cryptogenic/symptomatic 
generalized epilepsy (CGSE) in five patients-- 
who satisfied the diagnostic riteria for Lennox- 
Gastaut syndrome (LGS)2--and undetermined 
focal or generalized epilepsy (UFGE) in five 
patients. 
Complex partial seizures were the most com- 
mon seizure type (Table 1), and there was more 
than one seizure type in 41 patients (Table 2). 
The most common seizure combination in any 
individual patient was that of simple partial, 
complex partial and secondarily generalized 
tonic-clonic seizures in 15 patients, each of the 
five patients with CGSE (LGS) had aggregations 
of three to six (average four) different seizure 
types (Table 3). 
Seizures were recorded in a day to day seizure 
diary by the patient or care-giver, and were coded 
for seizure type. MSF was the mean seizure 
number over 28 days, calculated from the total 
number of seizures in the last three therapeuti- 
cally stable consecutive periods of 28 days. 
Antiepileptic response was expressed as the 
Table 1: Seizure diagnosis in patients (N = 42) treated with 
CVG and LTG in combination 
Seizure type Number of Percentage 
patients 
Complex partial 38 90 
Secondarily generalized 29 69 
Tonic-Clonic 
Simple partial 22 52 
Ton ic 12 29 
Atypical absences 10 24 
Atonic 6 14 
Tonic-clonic (undetermined) 4 10 
Myoclonic 3 7 
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Table 2: Aggregation of seizure types in patients (N = 42) 
treated with GVG and LTG in combination 
Number of seizure types Number of Percentage 
patients 
3 20 48 
2 13 31 
4 4 10 
5 3 7 
6 1 2 
1 1 2 
percentage change in MSF comparing phase III 
with phases I and II and phase II with phase I. 
PROTOCOL 
Three treatment phases were evaluated compris- 
ing the last three months of stable AED dosage. 
Phase I was a retrospectively analysed period 
(median duration three months; range, 1.3-15 
months) when patients were maintained on 
constant conventional antiepileptic therapy as a 
baseline. In phase II, (median duration 4.3 
months; range, 0.1-18.2 months) either GVG (in 
27 patients) or LTG (in 15 patients) was added to 
constant baseline AEDs with the plasma LTG 
level maintained from 2 to 3 mg/l. In phase III 
(median duration of 8 months; range, 0.5-18 
months) the second new drug (LTG or GVG) was 
added in increments of 50-100 mg/day of LTG or 
500-1000 mg of GVG every 2-4 weeks over 1-12 
weeks until seizure frequency was halved or 
adverse effects occurred. The main criterion for 
adding the second new drug in phase III was 
failure to achieve an adequate improvement in 
seizure control (as least a 50% reduction of phase 
I MSF) following the addition of the first new 
drug in phase II. During phase III the baseline 
conventional AEDs were reduced in 34 patients 
in an attempt o minimize the adverse effects of 
'polypharmacy'. VPA was taken by a total of 30 
patients during phase III and was added to the 
AED regimen of 17 patients to maintain or 
Table 3: Seizure diagnosis in patients (N = 5) with 
cryptogenic/symptomatic generalized epilepsy (LGS)* 
Seizure type Number of Percentage 
patients 
Tonic-clonic 5 100 
Tonic 4 80 
A typical absence 4 80 
Atonic 2 40 
Myoclonic 2 40 
* Each patient with Lennox-Gastaut Syndrome (LGS) had 
aggregations of 3-6 (mean, 4) different seizure types. 
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elevate the plasma LTG level in advance of 
progressive withdrawal of enzyme inducing 
AEDs. In 15 patients PHT was associated with 
depressed plasma LTG level relative to dose, with 
an elimination plasma half-life of four hours in 
one patient. Combination GVG and LTG the 
rapy was established with reduction of conven 
tional AEDs during hospitalization i half the 
patients and in an outpatient environment in the 
other half. 
Antiepileptic drugs 
The average number of conventional AEDs per 
patient was two (range, one to four) as shown in 
Table 4. 
ADVERSE EVENTS 
Regular clinical assessment and monitoring of full 
blood count, routine plasma biochemistry, urin 
alysis and microurine were carried out through 
out the study. EEGs were performed on all 
patients as part of their diagnostic epilepsy 
management and neuropsychological cognitive 
assessment, psychiatric evaluation and der- 
matological consultations were obtained at ap- 
propriate intervals or when indicated. 
PLASMA LAMOTRIGINE LEVEL 
The plasma LTG therapeutic window in phase III 
was estimated as follows. Trough plasma LTG 
levels were analysed in 28 patients, on samples 
collected when their median MSF fell by 50% or 
more in phase III, compared with phase I. The 
plasma LTG levels were also analysed in 16 
patients when they developed adverse events 
which were circumstantially related to an increase 
Table 4: Aggregation of baseline conventional AEDS in 
phase I of the audit 
AED Daily dose (mg) Number of Percentage 
mean range patients 
PHT 385 220-660 22 52 
CBZ 1 071 400-1 900 21 50 
VPA 1 947 l 000-3 500 16 38 
PRM 607 500-750 7 17 
CLN 2 1-4 3 7 
CLB 20 20-20 2 5 
PHT, phenytoin" CBZ, carbamazepine; VPA. sodium 
valproate: PRM, primidone: CLN, clonazepam: CLB, 
clobazam. 
in LTG dose, with remission on LTG dose 
reduction. The plasma LTG level was measured 
by a modified HPLC method with an interassay 
CV of less than 10% at or above the lover limit of 
sensitivity of 0.05 mg/l. LTG was analysed in 
500/zl aliquots of plasma by adding 1 ml of 2M 
sodium hydroxide, 1 ml of 0.8/zg/ml internal 
standard (BWA 725C) in ethylacetate and 8 ml of 
ethylacetate. The samples were vortexed for 30 
seconds and centrifuged at 2000rpm for 10 
minutes, the organic layer was transferred to a 
clean glass tube and evaporated to dryness at 
60°C under nitrogen. The dried residue was 
dissolved in 100/zl of ethanol, briefly vortexed 
and 20/zl injected onto the chromatographic 
column. Separation was achieved on a Dupont 
Zorbax straight phase silica column using a 
mobile phase of hexane ethanol ammonia 
solution, 800-200 to 2.5 by volume, at a flowrate 
of 2ml/minute. Detection was at a UV 
wavelength of 306 mM. 
STATISTICS 
Statistical significance of the differences in MSF 
between phases I and II, II and III and I and III, 
in the total population of 42 patients, was 
estimated by multiple comparison testing, using 
MBDP programme 3S ~. Comparisons were made 
between phase I, II, and III MSF values within 
individual patients to calculate the significance of 
the MSF reductions. The MSF histograms shown 
in Fig. 1 were constructed from the median values 
of the 42 patients in each of phases I, II and III. 
RESULTS 
A number of patients howed ramatic, sustained 
improvement in seizure control in phase III. 
There were two patients 'who became seizure free 
(100% seizure control), seven patients with 
90-99% seizure control and seven patients with 
80-89% seizure control. Thus 80-100% seizure 
control was achieved in 40% of the treated 
population. The median MSF in phase I was 29 
(range, 2-781; mean, 59; 95% CI 22, 96). There 
was a 37% reduction in MSF in phase II to a 
median value of 18 (range, 3-168; mean 34; 95% 
CI 22, 46) and a 39% additional reduction in 
median MSF to 11 (range, 0-275; mean 23; 95% 
CI 8, 38) in phase III, amounting to a 62% overall 
reduction in MSF in phase III, compared to that 
in phase I (Fig. 1). The reduction in median MSF 
from phases I to II did not achieve statistical 
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Fig. 1: Median MSF histograms in phases I, II and Ill, in the 
total population of 42 patients, treated with GVG and LTG as 
single (phase II) and then as combination (phase Ill) add-on 
therapy, compared to base-line conventional AEDs (phase 
I). MSF values of individual patients in phases I and II were 
not significantly different, whereas those in phases II and III 
and in phases I and II were significantly different from each 
other (P < 0.05 and P < 0.25, respectively). 
significance, but the reductions from II to III and 
I to III achieved significance at P<0.05 and 
P < 0.025, respectively. Table 6 shows the seizure 
frequencies and percentage seizure decreases 
during phases I, II and III for the three different 
epilepsy groups. The two groups with generalized 
epilepsy had almost three times the seizure 
frequency of the localization-related group in 
phase I. The seizure response varied in phase III 
according to epilepsy syndrome (Table 6). The 
percentage reduction in seizure frequency from 
phase II to phase III was comparable whether 
LTG was added to GVG in the majority of 27 
patients (38 and 62%, respectively) or GVG was 
added to LTG in the minority of 15 patients (42 
and 60%, respectively). Thus the sequence of 
addition of the second new drug did not appear to 
produce any difference in seizure reduction from 
phase II to phase III (Table 5). 
Adverse events were experienced in phase III 
by 24 patients (57%) and are listed in Table 7. 
The most clinically significant adverse events 
involved disturbances of higher cerebral function 
Table 5: Seizure response rate according to sequence of 
new drug 
Phase II Median seizure Phase III Median seizure 
reduction reduction 
GCG 42% GVG+ LTG 60% 
LTG 38% LTG +GVG 62% 
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Table 6: Seizure response rate according to epilepsy 
syndromal diagnosis 
Group Response Phase I Phase II Phase 111 
LRE MSF 
median 20 13 7 
range 2-228 4-168 0-265 
% decrease 35% 46% 
CGSE MSF 
median 66 55 23 
range 29-781 43-126 15-39 
% decrease 17% 58% 
UFGE MSF 
median 54 71 22 
range 15-58 9-90 4-35 
% decrease 31% 69% 
LRE, Localization-related pilepsy: CGSE, 
cryptogenic/symptomatic generalized epilepsy: UFGE. 
undetermined focal or generalized epilepsy. 
attributable to GVG, including aggressive be- 
haviour (12 patients), psychomotor retardation 
(eight patients), delusions (eight patients), im- 
paired memory (seven patients) and depression 
(seven patients). Aggressive personality change 
required discontinuation of GVG in three pati- 
ents. Dose-related adverse vents, attributable to 
LTG, included ataxia (15 patients), diplopia (ten 
patients), headache (eight patients) and vomiting 
(eight patients), which usually responded to dose 
reduction. Skin rash was circumstantially related 
to LTG in 11 patients (26%), appearing on 
average ten days after the commencement of the 
drug. It was usually a pruritic, papular ash on the 
Table 7: Adverse events in phase III 
Adverse Number of Incidence 
event Patients* 
Ataxia 15 36% 
Aggressive personality change 12 29% 
Rash 11 26% 
Diplopia/blurred vision 10 24% 
Clustering of seizures 10 24% 
Anorexia, nausea, vomiting 8 19% 
Headache 8 19% 
Psychomotor retardation 8 19% 
Delusions 8 19% 
Impaired memory 7 17% 
Depression 7 17% 
Drowsiness 6 14% 
Excessive weight gain 3 7% 
Tremor 3 7% 
Lower limb swelling 2 5% 
Pancytopenia 1 2% 
Abdominal distension 1 2% 
with constipation 1 2% 
Dysarthia 1 2% 
* Total number of patients = 42. 
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trunk and upper extremities and remitted in all 
but one patient while the drug was continued. 
However in one patient the rash was acneform, 
did not abate and was the reason why LTG was 
finally withdrawn. Seizure clustering, a marked 
(often several-fold) increase in seizure frequency 
over a relatively short period of time (e.g. 24-48 
hours) was viewed as an adverse event in ten 
patients. It frequently resulted in admission to 
hospital because of recurrence of atypical ab- 
senses (recurrent blank stares for an hour or 
more) and at times required short-term ben- 
zodiazepine (diazepam, clonazepam or clobazam) 
therapy. Increased appetite and excessive weight 
gain were noted in three patients in phase III 
(Table 7). There was a 12% drop-out rate (five 
patients) due to adverse vents in phase III. LTG 
was discontinued in one patient because of 
pancytopenia, which recurred on re-challenge, 
and her GVG was also withdrawn because of 
aggressive personality change and delusions. 
LTG was withdrawn in another patient because 
of skin rash. GVG was discontinued in 2 other 
patients because of psychomotor retardation and 
possible deterioration in seizure control with 
clustering. The fifth patient died suddenly in 
phase III when he fell from a building, possibly 
intentionally. 
The median trough plasma LTG level in the 
total population of 42 patients in phase III was 
9.9mg/l (range, 3.4-19.6mg/1). The median 
trough plasma LTG level at which the MSF fell by 
at least 50% in the responders was 7.9mg/l 
(range, 2.1-15.4 mg/l). The median plasma LTG 
level at which LTG dose-related side-effects, 
including ataxia, diplopia, dysarthria, headache 
and vomiting, appeared in phase III was 16.0 rag/1 
(range, 7.9-19.4mg/1). Thus a plasma LTG 
therapeutic window of 7.9-16.0mg/1 was indi- 
cated in phase III when patients were taking LTG 
in combination with GVG. Two patients exhib- 
ited LTG dose-related ataxia associated with 
disparate trough and post-dose plasma LTG 
values, in one patient 15.4 and 21.7 mg/l and in 
another 8.1 and 28.1 mg/l, respectively. 
DISCUSSION 
Conventional two-drug therapy is stated to be 
clearly effective in treating one in five patients 
with partial or tonic-clonic seizures who do not 
respond to monotherapy 9. The addition of LTG 
to GVG has been reported to result in con- 
siderable improvement in the seizure response 
rate of three patients with intractable secondary 
generalization of epilepsy which had failed to 
respond to temporal lobectomy 7. Recently 
placebo-controlled a dition of LTG to an AED 
regimen containing GVG resulted in a significant 
(37%) reduction in partial seizures, with nine of 
22 patients with refractory epilepsy reporting 
more than a 50% reduction by a maximal daily 
LTG dose of 200 mg and median plasma level of 
2.4 mg/l 1°. In the present study of patients with 
intractable pilepsy there was an additional 21% 
(overall 61%) improvement in seizure control, 
with a 50% or better improvement in seizure 
control in over two-thirds (69%) of 42 patients 
when LTG and GVG were combined with 
conventional AEDS, provided the trough plasma 
LTG level could be tolerated above 8mg/l. 
Sodium valproate (VPA) enabled this to be 
achieved in 40% of patients, presumably by 
inhibiting LTG metabolism which had been 
enhanced by auto-induction or induction by 
conventional AEDS such as phenytoin (PHT) 4. 
The therapeutic plasma concentration window for 
LTG in combination with GVG as add-on 
antiepileptic therapy was 7.9-16 mg/l. This prop- 
osed therapeutic range is significantly higher than 
that (1.5-3 mg/l) previously proposed 11 and that 
(1-7.9 mg/l) found in a recent placebo-controlled 
study j°. It reflects both a higher total daily dose of 
LTG and the frequent concomitant administra- 
tion of VPA, which appeared to be necessary to 
provide optimal seizure control in this population 
of patients with severe epilepsy. 
One cannot exclude the possibility that VPA 
added pharmacodynamic anti-seizure fficacy to 
the other AEDs in the 30 patients taking it in 
phase III, as reported in a patient with refractory 
generalized myoclonic epilepsy ~2. Another ex- 
planation for the unexpected improvement in 
seizure control might be the superior efficacy of 
VPA, GVG or LTG as monotherapy, particularly 
considering the relatively high plasma LTG levels 
achieved in the present study. This was not tested 
by consistently attempting to withdraw LTG or 
GVG in responders. Discontinuation of VPA was 
subsequently achieved in the face of compensa- 
tory increases in LTG dosage to maintain plasma 
LTG levels in half the valproate treated patients 
without obvious loss of seizure control. One 
cannot also exclude the possibility that discon- 
tinuation of baseline, conventional AEDs in 34 
patients during phase III altered seizure control. 
An attempt was made to minimize this possibility 
by introducing and increasing the investigational 
drugs (LTG and GVG) after adequate periods of 
therapeutic stability prior to decreasing conven- 
tional drugs and by making only one therapeutic 
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change at any one time. Non-compliance may 
have boen a factor in a few patients whose seizure 
control did not improve. However, plasma 
antiepileptic drug concentrations were generally 
consistent with dosage in most patients, whose 
motivation was probably relatively high in this 
selected population characterized by severe epi- 
epsy and previous drug trial experience. Non- 
compliance was therefore considered unlikely in 
the majority of these patients. 
The side-effect profile observed with this 
add-on combination of LTG and GVG was 
qualitatively comparable to that seen with con- 
ventional AEDs and similar to that reported for 
each new drug when administered as single 
add-on therapy 3'5, but the frequency of events 
was relatively high, with 57% of patients exhibit- 
ing a range of effects, including mild transient 
rash, headache, vomiting, occasional pancytope- 
nia and more dramatic behavioural disturbances, 
which were all reversible on drug withdrawal and 
resulted in a drop-out rate of only 12%. 
Offsetting this was the magnitude of the thera- 
peutic benefit in a patient population with severe, 
intractable elipeptic syndromes, indicating the 
need for further, controlled trials of this com- 
bination of novel AEDs to establish its value 
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